Regulatory Tag: Advocacy Opportunity

Discussions centered around evolving approaches to carrier compliance and oversight, reflecting an increasing shift toward data-driven system alignment.

Among many educational sessions, Sandy Shtab, Healthesystems VP of Industry and State Affairs, joined a panel on Medical Experience.

Senate Bill 1215 was discussed, and it appears unlikely the proposed reimbursement caps will be passed.

The committee issued new recommendations related to 300 mg ibuprofen, gabapentin and pregabalin, cyclobenzaprine, and tizanidine.

Matters discussed included physician dispensing, missed appointment fees, passive therapy utilization, and interpreter bill denials.

Stakeholders may send specific legislative recommendations to the DWC, if they are supported by data, and with relevant background or context.

The April 15th hybrid meeting will take place from 12:30 PM to 2:30 PM PST, covering a wide variety of pharmacy topics.

Two Oklahoma bills heading for House consideration would establish a NADAC based reimbursement floor, minimum dispensing fees, and a shortened 30 day payment timeframe.

While injured workers have an absolute choice over their pharmacist, physicians are not considered pharmacists and therefore not entitled to reimbursement.

At a March 11th meeting, the Workers’ Compensation Advisory Council announced a draft expected in fall of 2026 for public comments.

Interested stakeholders can submit comments on the proposal until April 28th.

The meeting covered potential updates to treatment guidelines, specifically for physical therapy, as well as other topics.

The meeting discussed proton pump inhibitors and the need to review utilization, and future meetings will address GLP-1 drugs, migraine drugs, and more.

Healthesystems played a significant role in reshaping policy surrounding reimbursement for physician dispensing.

After public feedback is received at the February 19th meeting, the fee schedule is expected to take effect March 15, 2026.